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Background: The substantia nigra (SN) midbrain nucleus is constitutively iron rich. Iron levels elevate further with
age, and pathologically in Parkinson’s disease (PD). Iron accumulation in PD SN involves dysfunction of
ceruloplasmin (CP), which normally promotes iron export. We previously showed that ceruloplasmin knockout
(CP KO) mice exhibit Parkinsonian neurodegeneration (~30% nigral loss) by 6 months, which is prevented by iron
chelation. Here, we explored whether known iron-stressors of the SN (1) aging and (2) MPTP, would exaggerate the
lesion severity of CP KO mice.
Findings: We show that while 5 month old CP KO mice exhibited nigral iron elevation and loss of SN neurons,
surprisingly, aging CP KO mice to 14 months did not exacerbate iron elevation or SN neuronal loss. Unlike young
mice, iron chelation therapy in CP KO mice between 9–14 months did not rescue neuronal loss. MPTP exaggerated
iron elevation in young CP KO mice but did not increase cell death when compared to WTs.
Conclusions: We conclude that there may exist a proportion of substantia nigra neurons that depend on CP for
protection against iron neurotoxicity and could be protected by iron-based therapeutics. Death of the remaining
neurons in Parkinson’s disease is likely caused by parallel disease mechanisms, which may call for additional
therapeutic options.
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Introduction
The substantia nigra pars compacta (SN) contains high
iron and dopamine levels even in healthy individuals [1],
which elevate further with age [2] and even more so in
PD patients [3-5]. Iron elevation in PD SN occurs early
in the disease [6], and correlates with motor disability
[7]. Iron accumulation also features in animal models of
PD such as MPTP intoxication, and likely contributes to
cell loss since iron chelation is neuroprotective [4,5]. Im-
portantly, iron chelation also improved motor symptoms
of PD in a 12-month Phase II clinical trial [8] also sug-
gesting that iron elevation confers neurotoxicity in the
disease. While these data support a role for iron in con-
tributing to the degenerative processes, it is unclear to* Correspondence: d.finkelstein@florey.edu.au
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unless otherwise stated.what extent iron causes cell death in the disease, or if
parallel disease mechanisms are more deleterious. Un-
derstanding the magnitude of iron-induced cell death in
the disease will inform us if targeting iron pharmaco-
logically will tangibly benefit PD patients.
Genetic disorders of brain-iron homeostasis can also
present as Parkinsonism [9-11], demonstrating that iron accu-
mulation can be a primary cause of PD-neurodegeneration.
Aceruloplasminemia is a rare genetic disorder caused by
loss of function mutations in ceruloplasmin (CP). CP is
the major copper-binding protein of plasma, but it func-
tions to maintain iron homeostasis. The protein coordi-
nates 6 copper atoms which enables electron transport
and reduction of oxygen to water, coupled with oxidation
of iron. This chemistry is used to facilitate cellular iron ex-
port. Aceruloplasminemia is characterized biochemically
by iron retention in brain and peripheral tissues, causing
various pathologies such as diabetes, Parkinsonism, and
dementia [12].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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CSF [17-19], and post-mortem SN tissue in PD [4]. Im-
paired CP activity, without the loss of CP abundance,
might be caused by oxidative damage to the protein
[19], leading to iron deposition in the disease. We and
others have previously modelled loss of CP activity using
CP knockout (KO) mice [4,20]; these mice develop iron-
dependent Parkinsonism before 6 months of age [4].
Here we explore if stressing iron homeostasis further in
CP KO mice with the PD toxin, MPTP, or by aging,
would exaggerate the PD phenotype, in order to under-




All animal experiments were approved by the Howard
Florey Animal Ethics Committee and were conducted in
accordance with state law and the Australian Code of
Practice for the Care and Use of Animals for Scientific
Purposes as described by the National Health and Medical
Research Council of Australia.
Mice
At the conclusion of each experiment, mice were trans-
cardially perfused with ice-cold PBS under deep anaes-
thesia (sodium pentobarbitone, 100 mg/kg). When blood
was harvested, it was collected in lithium heprin tubes.
Tissues were microdissected and analysed by inductively
coupled plasma mass spectrometry (ICP-MS; Additional
file 1: Supplementary Methods).
Ageing study
CP KO mice and background C57/Bl6 mice (WT) were
euthanized at either 5 or 14 months. Microdissected brain
was either sectioned for stereology or homogenized in
PBS and analysed for metals ICP-MS. Peripheral organs
were also homogenized in PBS for ICP-MS analysis.
Chronic chelation trial
9-month-old CP KO mice were administered either clio-
quinol (Cq) or deferiprone (DFP) iron chelators for five
months. DFP (Sigma Medical) was administered in drink-
ing water (≈100 mg/kg/day; ad libitum) as previously de-
scribed [4]. Mice treated with Cq were fed a diet of rodent
chow mixed with 0.25 g/kg (≈30 mg/kg/day; ad libitum) of
Cq (Specialty Feeds, Western Australia), as previously
described [5]. Mice were euthanized at 14 months of age
and midbrain was removed, sectioned and SN neurons
were counted using stereology.
MPTP trial
5-month-old WT and CP KO mice were administered
50 mg/kg MPTP (4 × 12.5 mg/kg, 2 hours apart, I.P.).24 hours later, mice of both genotypes were administered ei-
ther DFP (as described above) or purified ceruloplasmin
(CP) protein. CP was administered (5 mg/kg in saline, I.P.;
Vital products) twice weekly (day 2, 4, 8, 11, 15 & 18). After
21 days, mice were euthanized. Microdissected brain was ei-
ther sectioned for stereology or homogenized in PBS and
analysed for metals ICP-MS. Peripheral organs were also ho-
mogenized in PBS for ICP-MS analysis.
Results
Iron accumulation occurs in the brain with age [21]. First,
we explored whether this process was exaggerated in CP
KO mice, which have impaired iron export (Figure 1). Iron
was elevated in nigra (~20%, P = 0.034; Figure 1a) and
cerebellum (CB; ~40%, P = 0.002; Figure 1b) of 5-month-
old CP KO mice compared to WT mice, similar to find-
ings we reported for mice aged 6 months [4]. Aging mice
to 14 months caused iron to accumulate in both brain re-
gions of WT mice (SN: P < 0.001; CB: P < 0.001; Figure 1a,
b) so that CP KO mice at 14 months of age no longer had
significantly elevated iron in these regions compared to
similarly aged WTs. The stress of aging, therefore, did not
exaggerate iron accumulation in CP KO mouse brain
compared to WTs.
Iron accumulation in CP KO mice was most pro-
nounced in the liver, which is the major site of CP pro-
duction in the body. CP KO liver exhibited marked iron
elevation at both 5 (~500%, P < 0.001) and 14 months
(~900%, P < 0.001; Figure 1c). A trend toward iron eleva-
tion was observed in the spleen and heart of CP KO
mice at 5 months of age, which became significant at
14 months (Spleen:~50%, P = 0.005; Heart:~80%, P =
0.001; Figure 1d,e). Iron accumulation in peripheral tissues
of the CP KO mouse was, in contrast to brain tissue, more
apparent with age. Opposite to brain and peripheral tis-
sues, plasma iron was decreased in CP KO mice (~35% at
both 5 & 14 months, P < 0.001; Figure 1f). This may be
because iron export from tissues to plasma is restricted
due to the lack of CP, resulting in accumulation within tis-
sues, and a loss of iron in plasma. Elevated iron in brain,
and lower iron in plasma, is consistent with a Mendelian
Randomization study which showed SNPs that increased
serum iron levels decreased the risk for PD [4,22].
SN neuronal loss in 6 month old CP KO mice involves
iron elevation, since iron chelation ameliorates this lesion
[4,20]. We explored whether aging CP KO mice would
cause more pronounced neurodegeneration. 5-month-old
CP KO mice exhibited SN neurodegeneration (-25%, P <
0.001; Figure 2a) similar to our previous report [4] and
aging caused further SN neuronal loss in CP KO mice
(−32%, P < 0.001; Figure 2a). Only a further 7% of SN neu-
rons deteriorated in the 9 months after the initial time
point, demonstrating that the velocity of degeneration
was clearly slowed at 14 months of age. This coincided
Figure 1 Iron levels in CP KO mice tissue. WT and CP KO mice were aged to 5 and 14 months. Iron was measured in homogenized (a) substantia
ngira (b) cerebellum (c) liver (d) spleen and (e) heart by ICP-MS and corrected for tissue weight. (f) Plasma extract from blood was measured for iron
by ICP-MS. Data are mean ± std error. ‘n’ is represented in graph columns. *p < 0.05, **p < 0.01, ***p < 0.001 as indicated. ^p < 0.05, ^^^p < 0.001
relative to 5-month-old of the same genotype.
Figure 2 Nigral neurons in CP KO mice treated chronically with iron chelators. (a-c) WT and CP KO mice were aged to 5 and 14 months.
Mice were euthanized and brains were harvested and midbrains sectioned (a) representative WT nigra (b) representative CP KO nigra (c) Nissl
stained neurons were counted using stereology. (d) WT and CP KO mice were aged to 14 months. A sub-set of CP KO mice were treated with
Cq and DFP daily from 9 months of age. Mice were euthanized and brains were harvested and midbrains sectioned. Data are mean ± std error.
‘n’ is represented in graph columns. ***p < 0.001 as indicated. ^^p < 0.01 relative to 5-month-old of the same genotype.
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(Additional file 1: Figure S2a) and also increases in nigral
iron levels between genotypes of the same age (Figure 1a).
There was no difference between genotypes in cognitive
performance in the Y-maze at either age (Additional file 1:
Figure S2b).
To examine further the relationship between age and
SN neuronal loss in CP KO mice we explored if iron che-
lation therapy would ameliorate neuronal loss in older CP
KO mice, as it did in mice treated between 3 and 6 months
of age [4]. CP KO mice were treated with iron chelators,
deferiprone (DFP; 100 mg/kg/day) or clioquinol (Cq;
30 mg/kg/day), from 9 months of age until the experiment
was terminated when mice were aged 14 months. Both Cq
and DFP failed to rescue SN neuronal cell number over
the treatment period (Figure 2b).
Since the stress of aging did not exaggerate the vel-
ocity of SN neurodegeneration in CP KO mice, we hy-
pothesized that a certain proportion of SN neurons were
vulnerable to iron accumulation, and that these neurons
were lost early in CP KO mice. To test this, we adminis-
tered the PD toxin, MPTP, to WT and CP KO mice,
which causes loss of CP expression and consequent iron
elevation [4,23]. If the surviving SN neurons in CP KO
mice at 5 months of age were comparatively resistant to
iron toxicity, MPTP should not exaggerate nigral neuronal
loss. MPTP caused nigral iron accumulation in WT mice
(~30%, P < 0.001; Figure 3a), which was elevated further in
CP KO mice (~60%, P < 0.001; Figure 3a). MPTP caused
SN neuronal loss in both WT (−35%; P <0.001) and CP
KO (−20%; P <0.001). Despite the increased iron burden in
the MPTP-affected CP KO mice, neuronal loss in CP KO
mice did not exceed that of WT mice (~3500 remaining
neurons for both genotypes; P >0.05; Figure 3b).
We also investigated if targeting iron ameliorated
MPTP-mediated neuronal death in both genotypes. We
used two methods of targeting iron, CP supplementation
therapy, which promotes cellular iron export, and DFP,
which binds free iron. CP [4] and DFP [24] have beenFigure 3 MPTP-induced SN neuron loss in WT and CP KO mice is ame
administered MPTP (50 mg/kg, I.P.) and euthanized 21 days after. A sub-set
DFP during the experimental period. (a) RHS SN was microdissected and ir
Nissl stained neurons were counted by stereology. (c) Liver was harvested
represented in graph columns. *p < 0.05, ***p < 0.001 as indicated. ^p < 0.0shown previously to rescue MPTP neurotoxicity and, as
expected, lessened MPTP-induced neuronal loss in WT
and CP KO mice (Recovered to ~4100 neurons in each
case; Figure 3b). Rescue of iron elevation was evident in
CP KO mice for both CP and DFP (Figure 3a), but the
bulk iron levels in WT MPTP nigra were unchanged by
either treatment.
To test for drug specificity, we measured liver iron con-
tent in the same mice. MPTP did not change iron levels in
either WT or CP KO mice (Figure 3c). CP treatment did
not lower liver iron levels in either genotype, despite very
high levels of iron in CP KO liver. DFP treatment, how-
ever, lowered iron in both WTand CP KO liver.
Discussion
We hypothesized that iron-mediated neurodegeneration
caused by loss of CP would be exaggerated with the
stress of ageing, or with the MPTP toxin, which both in-
duce iron accumulation. However, we show that aging
slows the rate of SN iron accumulation (Figure 1a) and
consequent neurodegeneration (Figure 2a) in CP KO
mice, and MPTP fails to induce more pronounced neu-
rodegeneration in CP KO mice (Figure 3b), despite exag-
gerating iron elevation in their nigra (Figure 3a). We
propose that a proportion of SN neurons are more vul-
nerable to loss of CP, and associated iron neurotoxicity.
This has implications for understanding iron-induced
neurodegeneration in PD, and for pharmacologically tar-
geting iron in the disease.
It is unknown why iron elevates in the SN during the
aging process, but this could increase the susceptibility
for PD by causing oxidative stress (which is a feature of
the disease [25]) or possibly by Ferroptosis [26]. We
show that a proportion of SN neurons are vulnerable to
iron toxicity caused by genetic lesion (CP KO; Figure 2a),
or by a PD toxin (MPTP; Figure 2b). The vulnerability
of cells in this nucleus possibly explains why rare genetic
disorders of iron dyshomeostasis that cause brain-wide
iron elevation often present with Parkinsonism [9-11].liorated with CP or DFP. 5-month-old WT and CP KO mice were
of WT and CP KO mice were treated with dosing regimens of CP or
on was measured by ICP-MS. (b) LHS midbrain was sectioned and
and measured for iron by ICP-MS. Data are mean ± std error. ‘n’ is
5, ^^p < 0.01, ^^^p < 0.001 relative to control of the same genotype.
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therapies that target iron [4] (Figure 3a,b), which sup-
ports the use of iron-based therapies for PD.
Stressing the nigra of CP KO mice that already exhibit
iron-dependent neurodegeneration (5 month old) with
(1) iron accumulation caused by normal aging (Figure 2),
or (2) MPTP (Figure 3), did not exaggerate the loss of
SN neurons, suggesting that the surviving neurons are
resistant to iron-induced neurodegeneration. Possibly,
the neurons most vulnerable to MPTP-induced iron ele-
vation depend on CP to protect them, and that MPTP
induces a loss of CP [4] that causes these neurons to ac-
cumulate iron and die. The remaining neurons of the
SN do not rely as much on CP for protection possibly
because they have added defences against the conse-
quences of iron elevation.
In the MPTP model, two different pharmacological in-
terventions targeting iron (CP and DFP) were neuropro-
tective to CP KO and WT mice (Figure 3b), however we
observed that treatments only decreased bulk iron levels
in CP KO, not WT nigra (Figure 3a). Both CP and DFP
lower the neuronal labile iron pool, thus preventing
iron- redox interactions, so it is not necessary for bulk
iron levels to be reduced in DFP-treated animals for
DFP to confer neuroprotection by iron chelation. We
previously showed that CP supplementation lowered ni-
gral iron levels in MPTP-administered mice [4]. The CP
dosing regimen in the present work was different to our
previous study [4], concluding three days prior to ter-
mination of the experiment, which may have allowed
time for iron to accumulate.
Our current findings indicate that there are some SN
neurons that depend on CP expression to protect them
from iron induced death, and there other neurons that
have an alternative protection mechanism that does not
rely on CP. Therefore, there is an opportunity to treat
PD by pharmacologically removing iron that causes cell
death in vulnerable neurons. This is important because
iron-mediated neurodegeneration can be targeted by
established therapies, like iron chelation, or biological al-
ternatives such as ceruloplasmin therapy. Indeed, DFP is
the first drug to show slowing of the disease progression
in a clinical trial [8], which highlights the promise of this
approach. Since iron elevation did not exacerbate neur-
onal cell death beyond ~30% in our study it is likely that
parallel mechanisms contribute to the degenerative
process in PD. So while there is opportunity to treat
some cells of the SN with iron chelators, there likely ex-
ists a proportion of dying neurons in the disease that are
intractable to iron-based therapies.
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